Evaluation of Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis: A Phase IV, Prospective, Open Label, Multi-centric, Single Arm, Clinical Study. - Hepamerz
Secondary Prophylaxis of hepatic encephalopathy in cirrhosis:A double Blind randomized controlled trial of L-Ornithine L-Aspartate (LOLA) versus placebo - LOLA
100 Clinical Results associated with Win-Medicare Pvt Ltd.
0 Patents (Medical) associated with Win-Medicare Pvt Ltd.
100 Deals associated with Win-Medicare Pvt Ltd.
100 Translational Medicine associated with Win-Medicare Pvt Ltd.